Renal Cell Carcinoma
FDA Approves Opdivo Qvantig for Subcutaneous Injection
The FDA approved nivolumab plus hyaluronidase-nvhy (Opdivo Qvantig, Bristol Myers Squibb) for subcutaneous ...
DECEMBER 30, 2024
Choosing Later Lines Of mRCC Therapy A Mix of Art and Science
PHOENIX—Pharmacists have many guideline-directed options for front-line treatment of metastatic renal cell ...
MAY 12, 2023
Keytruda Gains Approval to Treat Patients With RCC After Nephrectomy
The FDA approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma ...
NOVEMBER 29, 2021
FDA Approves Bavencio With Inlyta for Patients With Advanced Renal Cell Carcinoma
Bavencio with Inlyta is the first FDA approval for an anti–PD-L1 therapy as part of a combination regimen for ...
MAY 16, 2019
Load more